Stomach Cancer Drugs Market is anticipated to grow with a value CAGR of 5.3% over 2019-2028. According to a study published by Insure Insights on the Stomach Cancer Drugs Market. Stomach cancer, is formation of abnormal cells that form a mass in part of stomach. It is accompanied by symptoms like fatigue, feeling bloated after eating, severe indigestion nausea, stomach pain, persistent vomiting, etc. There are various drugs used in Stomach Cancer treatment like Kinase Inhibitors, Nucleoside Metabolic Inhibitors, Anthracyclines etc. The rise in the geriatric population across the world and product launches have driven the market.

Top Driver: The Increasing FDA approvals of biosimilars for treatment of stomach cancer are making a significant contribution to the Market

The Increasing FDA approvals of biosimilars for treatment of stomach cancer and growing incidences of stomach cancer have highly contributed in the Market. The rise in the R&D activities and government initiatives in better healthcare have promoted the market.  The technological advances in the treatment of Stomach Cancer, the rise in the healthcare infrastructure along with improved healthcare expenditure have positively impacted the market growth.

Nucleoside Metabolic Inhibitors have obtained the highest growth in the Global Stomach Cancer Drugs Market

Based on Therapy Type, the Nucleoside Metabolic Inhibitors segment have held the most significant growth. Nucleoside Metabolic Inhibitors, they work by slowing down the growth of cancer cells which then kills the cell and thus controls the cancer. The segment is expected to exhibit a remarkable share in the forecast

Based on Treatment, targeted drugs therapy segment have held in the lucrative share owing to the availability of various targeted techniques like as stem cell therapy, immunotherapy, or enzyme therapy. In terms of Distribution Channel, Hospitals Pharmacy segment has held the highest share owing to the rise in the patent pool in hospitals.

North America to rule the Regional Market due to the rise in the occurrence of Stomach Cancer

The rise, in the occurrence of stomach Cancer along with the presence of key players like Eli Lilly and Company, Pfizer Inc., Gilead Science Inc., etc. have primarily improved the market of North America, the rise in Government spending, favorable reimbursement for advanced healthcare, Increased R&D expenditure, are expanding the market growth in the region. The Asia Pacific region is projected to growth at a faster rate owing to the growth in the geriatric population and technological advances in various therapies for stomach cancer in the region.

Players to Focus on advancing the technologies, Product Launches, and signing merger and acquisition deals for enhancing the treatment activities

The Competitors are focusing on developing new technologies for enhancing the treatment capabilities, product launches, and signing merger and acquisition deals. The major competitors of the Stomach Cancer Drugs Market are Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Kuhnil Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck KGaA, AstraZeneca Plc, Otsuka Holdings Co. Ltd., Sanofi S.A., and Roche Ltd,

Pfizer Inc.:  Pfizer Inc., is the leading competitor of the Stomach Cancer Drugs Market. For instance, in July 2019, Pfizer Inc., had announced the acquisition of ARRAY BIOPHARMA, the deal was made for USD 11.4 billion. This acquisition was made to strengthen its portfolio in oncology treatment

Roche: Roche is one of the popular competitor of the Stomach Cancer Drugs Market. In 2018, Roche had announced that it has completed acquisition Flatiron Health., the deal was made for USD 1.9 billion. The acquisition was made to strengthen its capabilities in Oncology.

 Scope of the Report

By Therapy Type

• Kinase Inhibitors
• Nucleoside Metabolic Inhibitors
• Anthracyclines
• Others

By Treatment

• Surgery
• Chemotherapy
• Adjuvant chemotherapy
• Targeted drugs therapy
• Radiation therapy

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region

• North America
• Europe
• Asia Pacific
• SAMEA

Key Reasons to Purchase this Report

1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.